Our research activities are focused on the development of therapeutic agents to treat a group of blood cancers called myeloproliferative neoplasms (MPNs). Three closely related but clinically distinct diseases belong to MPNs: polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). Acquired gene mutations of the hematopoietic stem cells are responsible for MPNs causing chronic overproduction of blood cells. MPNs are prone to thrombosis, bleeding and patients frequently transform to acute myeloid leukemia.


The genes mutated in MPN (JAK2, CALR and MPL) have already been identified and MyeloPro founders Robert Kralovics and Stefan Constantinescu were among the lead researchers behind these discoveries. MyeloPro’s research focuses on the development of antibodies that target the mutated form of the protein called calreticulin (CALR). Although CALR immunotherapy is our main focus, we also searching for small molecules that can selectively target hematopoietic cells with the CALR or JAK2 mutations.